Everyday Health on MSN

Speech therapy for your mild cognitive impairment (MCI)

Explore how speech therapy assists those with mild cognitive impairment (MCI) in overcoming communication challenges. Learn about important lifestyle measures and finding a therapist.
GlobalData on MSN

FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s …

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
MPR

Subcutaneous Lecanemab Starting Dose Under Review for Alzheimer Disease

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

Eisai Inc.: FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi ...
Rutgers University

Rutgers Health Begins Clinical Trial to Determine if B1 Can Slow Alzheimer’s Disease

Researchers at Rutgers Robert Wood Johnson Medical School in New Brunswick are enrolling participants in the National ...

IGC Pharma adds New York site for Alzheimer’s disease trial

"IGC Pharma adds New York site for Alzheimer’s disease trial" was originally created and published by Clinical Trials Arena, ...